GAMMAGARD LIQUID IV
Learn more about intravenous (IV) administration of GAMMAGARD LIQUID
Protect life's moments with:
- An established safety profile1
- Sustained protection against infection1,2
- An established tolerability profile
- Maintenance of consistent lgG serum through levels during the 12 months of treatment1,2
Selected Important Risk Information
- The serious adverse reaction that occurred during the PI (IV administration) clinical trials was aseptic meningitis.
- The most common adverse reactions observed in ≥ 5% of patients in the PI (IV administration) clinical trials were: Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur.
References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Church JA, Leibl H, Stein MR, et al, and the US-PID-IGIV 10%-Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IVIG 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388-395.
Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
Find Out How
Get training support from our Nurse
Advocates on intravenous and subcutaneous administration of GAMMAGARD LIQUID.
Call 1-855-250-5111 to talk to a